Lista de obras - Guillermo Montalban-Bravo

A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents

artículo científico publicado en 2018

A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN.

artículo científico publicado en 2017

Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia

artículo científico publicado en 2020

Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome

artículo científico publicado en 2019

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

artículo científico publicado en 2020

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms

artículo científico publicado en 2018

Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2019

Management of myelodysplastic syndromes after failure of response to hypomethylating agents.

artículo científico publicado en 2019

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

artículo científico publicado en 2017

Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management

artículo científico publicado en 2020

Natural History of Newly Diagnosed Myelodysplastic Syndrome with Isolated Inv(3)/t(3;3)

artículo científico publicado en 2020

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents

artículo científico publicado en 2017

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

scientific article published on 28 February 2020

Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes

artículo científico publicado en 2017

Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

artículo científico publicado en 2022

TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens

artículo científico publicado en 2017

The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes

artículo científico publicado en 2020

Lista de obras de Guillermo Montalban-Bravo

A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents

A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN.

Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia

Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms

Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia

Management of myelodysplastic syndromes after failure of response to hypomethylating agents.

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management

Natural History of Newly Diagnosed Myelodysplastic Syndrome with Isolated Inv(3)/t(3;3)

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes

Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens

The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes

mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy